Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Bachy, Emmanuel  [Clear All Filters]
2024
Dreyling M, Fowler NH, Dickinson M, Martínez-López J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, et al. Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update. Blood. 2024.
Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas R-O, Ysebaert L, Damaj GLaurent, Guidez S, Pica GMatteo, Kim WSeog, et al. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. J Clin Oncol. 2024:JCO2301687.
2023
Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. 2023.
Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Santos DMCordas D, Freeman CL, Alsina M, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023;16(1):88.
Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023.
2022
Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Buecklein V, Trenker C, Hernani R, Naumann R, Schäfer JA, et al. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022.
2021
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, Damaj G, Guidez S, Pica GMatteo, Kim WSeog, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2021:JCO2101815.
2020
Sesques P, Bourcier J, Golfier C, Lebras L, Nicolas-Virelizier E, Hacini M, Perrin MClaire, Voillat L, Bachy E, Traverse-Glehen A, et al. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematol Oncol. 2020.